E508 | Paolo Pio, Exceptional Ventures: Betting on Better Humans: Inside Exceptional Ventures’ Health & Longevity Playbook

Welcome to a new episode of the EUVC Podcast, where we bring you the people and perspectives shaping European venture.This week, sits down with , co-founder and Managing Partner at — a mission-driven early-stage fund investing in the future of human health, fitness, nutrition, and longevity.Paolo shares how a personal obsession with sleep, metabolism, and fitness evolved into a structured thesis for investing in businesses and technologies that help us live better, longer — and how Exceptional Ventures plans to back over 200 founders across three funds to deliver returns that match the mission.🎯 This Episode’s Themes:Why health, fitness, and prevention are ripe for VC investmentHow personalized, continuous monitoring unlocks true wellnessThe 4-pillared thesis: prevention, early detection, smarter care & deliveryLessons from Fund I: 3,600 companies reviewed → 37 investmentsThe case for “high-volume VC” in Europe: why more bets matterFrom sleep hygiene to nanobots: the future of health innovationCommunity, LPs, and morning workouts at SuperVentureHere’s what’s covered:01:00 | The Mission: Improving the human joy path through health & longevity03:00 | Why Now: Obesity, metabolic health & the need for smarter prevention05:00 | The Four Pillars: Sleep, exercise, early detection & delivery innovation08:00 | Exceptional’s Model: Fund I learnings, Fund II targets, Fund III ambitions10:00 | The Volume Bet: Why Europe needs funds backing 50+ startups per cycle12:00 | Sourcing & Screening: From 3,600 companies to 37 portfolio bets15:00 | Backing Founders on the Edge: From glucose monitoring to rural US clinics18:00 | The Big Vision: 200+ founders backed, 30,000+ community members21:00 | Big LP Names & Co-Investors: How the wider venture stack leans in24:00 | Why Community Matters: The morning workouts, the events, the energy27:00 | Longevity & Fund IV: Why the best is still ahead

There are no comments yet.

Please log in to write the first comment.